Achieve Life Sciences

Squarepoint Ops LLC bought a new stake in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 17,519 shares of the biopharmaceutical company’s stock, valued at approximately $62,000. Squarepoint Ops LLC owned 0.05% of Achieve Life Sciences at the end of the most recent reporting period. A number of other hedge funds and other institutional investors have also bought and sold shares of ACHV. Tower Research Capital LLC TRC raised its holdings in Achieve Life Sciences by 185.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,545 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 4,905 shares during the period. Sigma Planning Corp bought a new stake in Achieve Life Sciences during the 4th quarter valued at $37,000. ADAR1 Capital Management LLC raised its holdings in Achieve Life Sciences by 14,375.8% during the 4th quarter. ADAR1 Capital Management LLC now owns 13,173 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 13,082 shares during the period. SBI Securities Co. Ltd. bought a new stake in Achieve Life Sciences during the 4th quarter valued at $49,000. Finally, Intech Investment Management LLC bought a new stake in Achieve Life Sciences during the 4th quarter valued at $58,000. Institutional investors own 33.52% of the company’s stock. Insider Buying and Selling In related news, CFO Mark K. Oki bought 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of $2.89 per share, for a total transaction of $28,900.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares of the company’s stock, valued at approximately $28,900. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.00% of the stock is owned by company insiders. Achieve Life Sciences Trading Down 1.9% Shares of ACHV stock opened at $3.69 on Wednesday. The company’s fifty day simple moving average is $2.72 and its two-hundred day simple moving average is $3.16. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.78 and a quick ratio of 6.78. Achieve Life Sciences, Inc. has a 1 year low of $1.84 and a 1 year high of $5.38. The stock has a market capitalization of $127.99 million, a price-to-earnings ratio of -3.27 and a beta of 1.63. Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.37) EPS for the quarter, meeting analysts’ consensus estimates of ($0.37). As a group, analysts anticipate that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current year. Achieve Life Sciences Company Profile (Free Report) Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.» Mehr auf defenseworld.net

Achieve Life Sciences (ACHV) is positioned for growth with its lead smoking cessation therapy, cytisinicline, advancing through late-stage clinical trials. The company addresses a significant unmet need in tobacco addiction, with cytisinicline showing promising efficacy and safety data compared to existing therapies. While FDA approval may be difficult, the low valuation and high potential peak sales provide a decent risk/reward profile.» Mehr auf seekingalpha.com

SEATTLE and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that the company will present at the Jefferies Global Healthcare Conference being held June 3–5, 2025, in New York City.» Mehr auf globenewswire.com